The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CAPS | -96.11% | -96.11% | -40.85% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +1,480% |
Capstone Therapeutics Corp. is a biotechnology company. It develops a pipeline of novel therapeutic peptides and other molecules aimed at helping patients with under-served medical conditions. The company was founded in July 1987 and is headquartered in Alsip, IL.
No news articles found for Capstone.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.65M | 10.8% |
| Gross Profit | $3.14M | 4.8% |
| Gross Margin | 22.97% | -1.3% |
| Market Cap | $8.26M | 0.0% |
| Market Cap / Employee | $206.53K | 0.0% |
| Employees | 40 | 0.0% |
| Net Income | -$2,014.00K | -6023.5% |
| EBITDA | $2.00K | -99.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $730.00K | 5515.4% |
| Accounts Receivable | $5.77M | 19.9% |
| Inventory | 12.2 | 9.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.04M | 24.7% |
| Short Term Debt | $13.22M | 18.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.08% | -4.0% |
| Return On Invested Capital | 2.73% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.00K | -100.0% |
| Operating Free Cash Flow | $0.00K | -100.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -0.12 | 0.35 | 0.27 | - | |
| Price to Sales | 0.01 | 0.29 | 0.22 | 0.17 | 1335.95% |
| Price to Tangible Book Value | -0.01 | 2.58 | 2.44 | - | |
| Price to Free Cash Flow TTM | 0.23 | 0.10 | 4.43 | 8.81 | 615.86% |
| Enterprise Value to EBITDA | -461.36 | -23.26 | -203.61 | 15979.64 | 16312.92% |
| Free Cash Flow Yield | 435.9% | 978.4% | 22.6% | 11.3% | -86.03% |
| Return on Equity | -9.2% | -11.6% | -13.0% | -20.2% | 70.97% |
| Total Debt | $16.61M | $19.76M | $20.74M | $23.26M | 21.25% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
